GeneDx Holdings Corp (WGS)
19.66
+0.16
(+0.82%)
USD |
NASDAQ |
May 03, 16:00
19.76
+0.10
(+0.48%)
After-Hours: 20:00
GeneDx Holdings Cash from Financing (TTM): 53.14M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 53.14M |
December 31, 2023 | 186.24M |
September 30, 2023 | 139.20M |
June 30, 2023 | 139.46M |
March 31, 2023 | 330.13M |
Date | Value |
---|---|
December 31, 2022 | 197.32M |
September 30, 2022 | 196.22M |
June 30, 2022 | 696.27M |
March 31, 2022 | 495.85M |
December 31, 2021 | 493.73M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
53.14M
Minimum
Mar 2024
696.27M
Maximum
Jun 2022
292.76M
Average
196.77M
Median
Cash from Financing (TTM) Benchmarks
American Well Corp | 2.147M |
GoodRx Holdings Inc | -167.40M |
Privia Health Group Inc | 3.705M |
Doximity Inc | -274.31M |
GE HealthCare Technologies Inc | -1.304B |